RNA Tumor Therapy Composition for Stable Intratumoral Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments using DNA as a gene therapeutic agent pose risks of genomic integration and immune responses, while RNA-based treatments face instability issues due to ribonucleases and other degradation processes.
Innovation Solution
Development of an RNA-containing composition, specifically designed for intratumoral application, which includes coding and non-coding RNAs to stimulate the immune system and target cancer cells, utilizing chemically modified RNAs and adjuvants to enhance stability and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If DNA is used as a gene therapeutic agent, then genetic information can be transferred into cells, but there is a risk of DNA being integrated into the host cell genome causing mutations or inducing pathogenic anti-drug antibodies
Solution Approach 1:
The patent extracts the therapeutic genetic information from DNA and transfers it to RNA molecules. By using RNA instead of DNA as the gene delivery vehicle, the invention eliminates the risk of genomic integration while preserving the ability to transfer and express therapeutic genetic information in target cells
Solution Approach 2:
The patent introduces RNA as an intermediary carrier between the genetic information source and the target cell. This RNA mediator performs the function of genetic information transfer and protein expression without the harmful side effects associated with DNA, specifically avoiding genomic integration and pathogenic antibody induction
2Reliability
If RNA is used as a gene therapeutic agent, then the risk of genomic integration and anti-drug antibody induction is eliminated, but the instability of RNA due to ribonucleases and degradation processes becomes a problem
Solution Approach 1:
The patent creates composite RNA structures by combining multiple RNA molecules with different functions into a single composition. This includes antigen-coding RNA for therapeutic effect, immunostimulatory RNA for immune activation, and stabilizing RNA components. The composite structure provides both the therapeutic benefits and enhanced stability needed for effective gene therapy
Solution Approach 2:
The patent modifies the chemical and structural parameters of RNA molecules to enhance stability. This includes using chemically modified nucleotides, adjusting RNA secondary structures, and optimizing RNA sequence composition to resist ribonuclease degradation while maintaining functional activity
3Quantity of substance
If conventional DNA-based gene therapy methods are used, then genetic information transfer is achieved, but the complexity of delivery methods and potential harmful effects increase
Solution Approach 1:
The patent uses RNA as a simplified intermediary that naturally performs genetic information transfer without requiring complex viral vectors or transfection mechanisms. The RNA molecules can be delivered directly to cells and naturally processed by cellular machinery, reducing the complexity of the delivery system compared to DNA-based approaches
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The RNA composition effectively reduces tumor size and increases survival in animal models by inducing a targeted immune response against cancer cells, overcoming stability challenges and minimizing genomic integration risks.
Implementation Method 1
The RNA containing composition effectively reduces tumor size and increases survival in animal models by inducing a targeted immune response against cancer cells
Data Source
AI summary
The present invention relates to RNA containing compositions for use in the treatment or prophylaxis of tumor and/or cancer diseases, to a pharmaceutical composition, to a kit and to uses of the RNA containing compositions for the treatment or prophylaxis of tumor and/or cancer diseases.